



## Neurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015

May 12, 2015

### Live Audio Webcast Will be on May 21, 2015

SAN DIEGO, May 12, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will host an Analyst and Investor Day at the New York Palace Hotel in New York City on Thursday May 21, 2015 from 12:00 p.m. to 3:30 p.m. ET (9:00 a.m. to 12:30 p.m. PT).

Presenters will include:

- Kevin Gorman, President and Chief Executive Officer
- Timothy Coughlin, Chief Financial Officer
- Christopher O'Brien, Chief Medical Officer
- Kyle Gano, Chief Business Development Officer
- Dimitri Grigoriadis, Chief Research Officer
- Sylvia Hannaman, Director of Market Research and Planning
- Dr. Bruce Carr, MD, Professor of Obstetrics and Gynecology at UT Southwestern Medical Center
- Dr. Stewart Factor, Professor of Neurology Director, Emory Comprehensive Parkinson's Disease Center and the Movement Disorders Program
- Dr. Karen Lin Su, Medical Director Cares Foundation

To attend the live event at the New York Palace Hotel, please contact Neurocrine investor relations at [ir@neurocrine.com](mailto:ir@neurocrine.com).

To access the webcast on May 21, go to the homepage on [www.neurocrine.com](http://www.neurocrine.com) and click on the Webcasts & Presentations box to access the link. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

### About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-host-analyst-and-investor-day-in-new-york-city-on-may-21-2015-300082056.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Investor Relations, (858) 617-7600